The cancer diagnostics technology developer, formed five years ago when Qiagen acquired part of Enzymatics, has filed to float on the Nasdaq Global Market.
US-based genomic testing technology developer ArcherDX has filed to raise up to $100m in an initial public offering that would allow medical researcher Qiagen to exit. ArcherDX has developed a system targeted at cancer that applies advanced genetic sequencing technology and bioinformatics software to the identification and discovery of genetic mutations. The company was launched…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
